Collagen type II-specific T-cell receptor (CII-specific TCR)

The Collagen type II-specific T-cell receptor (CII-specific TCR) is a critical mediator in the development and progression of rheumatoid arthritis (RA). It functions by recognizing specific fragments of type II collagen, most notably the immunodominant CII(259–273) epitope, when presented by Major Histocompatibility Complex (MHC) class II molecules like HLA-DR4 or HLA-DR1 on antigen-presenting cells (Ciesielski et al., 2001, Journal of Immunology). This recognition triggers the activation of autoreactive CD4+ T-cells, which orchestrate an inflammatory cascade leading to synovial hyperplasia and the degradation of joint cartilage and bone (Rosloniec et al., 2011, Journal of Immunology). As a therapeutic target, the CII-specific TCR is the focus of antigen-specific immunotherapies designed to restore immune tolerance rather than providing broad immunosuppression. Strategies include the administration of oral or intradermal type II collagen to induce mucosal tolerance, as well as the use of peptide-loaded tolerogenic dendritic cells or TCR-like antibodies to block the interaction (Backlund et al., 2002, PNAS). By specifically targeting the T-cells responsible for the autoimmune attack on joint collagen, these therapies aim to provide long-term remission with fewer systemic side effects than conventional disease-modifying antirheumatic drugs (DMARDs).

Other names

Collagen II-reactive T-cell receptorAnti-CII TCRCII-specific T-cell receptor recognition complexType II collagen-specific TCR

Induction of antigen-specific immune tolerance, T-cell anergy, or deletion of autoreactive T-cells to prevent joint destruction.